Kymera Therapeutics Stock Options
| KYMR Stock | USD 40.61 0.32 0.79% |
Kymera Therapeutics' latest option contracts expiring on March 21st 2025 are carrying combined implied volatility of 0.92 with a put-to-call open interest ratio of 0.5 over 20 outstanding agreements suggesting investors are buying more calls than puts on contracts expiring on March 21st 2025.
Open Interest Against March 21st 2025 Option Contracts
2025-03-21
The chart above shows Kymera Therapeutics' distribution of open interest by maturity on contracts that have not yet been settled. The area between the two highest points is the projection of the price at expiration. Kymera Therapeutics' open interest chart also provides vital information regarding the liquidity of an option. If there is no open interest for Kymera Therapeutics' option, there is no secondary market available for investors to trade.
Kymera Therapeutics Maximum Pain Price Across 2025-03-21 Option Contracts
Max pain occurs when Kymera Therapeutics' market makers reach a net positive position across all Kymera Therapeutics' options at a strike price where option holders stand to lose the most money. By contrast, Kymera Therapeutics' option sellers may reap the most after selling more options than buying, causing them to expire worthless.
In The Money vs. Out of Money Option Contracts on Kymera Therapeutics
Analyzing Kymera Therapeutics' in-the-money options over time can help investors to take a profitable long position in Kymera Therapeutics regardless of its overall volatility. This is especially true when Kymera Therapeutics' options are deep in the money. These options can be identified using deltas that are over 0.75. Deep in-the-money Kymera Therapeutics' options could be used as guardians of the underlying stock as they move almost dollar for dollar with Kymera Therapeutics' stock while costing only a fraction of its price.
Kymera Therapeutics In The Money Call Balance
When Kymera Therapeutics' strike price is surpassing the current stock price, the option contract against Kymera Therapeutics stock is said to be in the money. When it comes to buying Kymera Therapeutics' options that are 'In the Money' or 'Out of the Money', the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
While 'out-of-the-money' option contracts written on Kymera Therapeutics are typically viewed as the more aggressive, there are potential upsides to purchasing these types of options contracts. For one, the cost to buy an 'Out of the Money' option is lower than the cost to buy an 'In the Money' option. This cost-benefit is due to the fact that at the time of the purchase, 'Out of the Money' contracts have no intrinsic value. So, while the potential for a 100% loss is more significant, the cost and risk to enter the trade are lower.
Kymera Current Options Market Mood
Kymera Therapeutics' open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps Kymera Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.
Put-to-Call Open Interest
Put-to-Call Volume
Unfortunately, most Kymera Therapeutics' options investors are not very successful. Kymera Therapeutics' option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction.
Rule 16 of the current Kymera contract
Base on the Rule 16, the options market is currently suggesting that Kymera Therapeutics will have an average daily up or down price movement of about 0.0575% per day over the life of the 2025-03-21 option contract. With Kymera Therapeutics trading at USD 40.61, that is roughly USD 0.0234. If you think that the market is fully incorporating Kymera Therapeutics' daily price movement you should consider buying Kymera Therapeutics options at the current volatility level of 0.92%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Kymera |
Purchasing Kymera Therapeutics options can give investors a meaningful hedge against losses and, therefore, could be used conservatively to decrease the volatility of your portfolio. However, many options could also amount to little more than gambling, significantly enhancing your overall portfolio risk. One simple example of these aggressive strategies is the sale of "uncovered" Kymera calls. Remember, the seller must deliver Kymera Therapeutics stock to the call owner when a call is exercised.
Kymera Therapeutics Option Chain
When Kymera Therapeutics' strike price is surpassing the current stock price, the option contract against Kymera Therapeutics stock is said to be in the money. When it comes to buying options that are ITM or OTM, the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
Kymera Therapeutics' option chain is a display of a range of information that helps investors for ways to trade options on Kymera. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for Kymera. It also shows strike prices and maturity days for a Kymera Therapeutics against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone. | Open Int | Strike Price | Current Spread | Last Price | |||
Call | KYMR250321C00022500 | 0 | 22.5 | 16.6 - 21.0 | 16.6 | In |
Call | KYMR250321C00025000 | 0 | 25.0 | 14.4 - 18.3 | 14.4 | In |
Call | KYMR250321C00030000 | 0 | 30.0 | 9.7 - 13.9 | 9.7 | In |
Call | KYMR250321C00035000 | 0 | 35.0 | 5.7 - 10.0 | 5.7 | In |
Call | KYMR250321C00040000 | 0 | 40.0 | 2.7 - 7.0 | 2.7 | In |
Call | KYMR250321C00045000 | 1 | 45.0 | 0.4 - 4.9 | 3.8 | Out |
Call | KYMR250321C00050000 | 0 | 50.0 | 0.2 - 4.9 | 0.2 | |
Call | KYMR250321C00055000 | 1 | 55.0 | 0.0 - 4.9 | 1.5 | Out |
Call | KYMR250321C00060000 | 0 | 60.0 | 0.0 - 4.9 | 4.9 | |
Call | KYMR250321C00065000 | 0 | 65.0 | 0.0 - 4.9 | 4.9 | |
Put | KYMR250321P00022500 | 0 | 22.5 | 0.0 - 4.9 | 4.9 | |
Put | KYMR250321P00025000 | 0 | 25.0 | 0.0 - 4.9 | 4.9 | |
Put | KYMR250321P00030000 | 0 | 30.0 | 0.0 - 4.9 | 4.9 | |
Put | KYMR250321P00035000 | 0 | 35.0 | 0.1 - 4.9 | 0.1 | |
Put | KYMR250321P00040000 | 0 | 40.0 | 1.2 - 5.8 | 1.2 | |
Put | KYMR250321P00045000 | 1 | 45.0 | 4.0 - 8.7 | 6.0 | In |
Put | KYMR250321P00050000 | 0 | 50.0 | 7.5 - 12.3 | 7.5 | In |
Put | KYMR250321P00055000 | 0 | 55.0 | 12.2 - 16.5 | 12.2 | In |
Put | KYMR250321P00060000 | 0 | 60.0 | 17.8 - 21.3 | 17.8 | In |
Put | KYMR250321P00065000 | 0 | 65.0 | 22.2 - 26.0 | 22.2 | In |
Kymera Total Stockholder Equity
Total Stockholder Equity |
|
Kymera Therapeutics Corporate Management
| Jared MD | Chief Officer | Profile | |
| DPhil DPHIL | CoFounder Chairman | Profile | |
| JD Esq | Chief Secretary | Profile | |
| Karen Weisbach | Head Culture | Profile | |
| Juliet BA | Head Research | Profile | |
| Melissa Brody | VP Devel | Profile | |
| Elaine Caughey | Chief Officer | Profile |
Additional Tools for Kymera Stock Analysis
When running Kymera Therapeutics' price analysis, check to measure Kymera Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kymera Therapeutics is operating at the current time. Most of Kymera Therapeutics' value examination focuses on studying past and present price action to predict the probability of Kymera Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kymera Therapeutics' price. Additionally, you may evaluate how the addition of Kymera Therapeutics to your portfolios can decrease your overall portfolio volatility.